Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 in Active Ankylosing Spondylitis
CTR20210833Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of gumokimab in ankylosing spondylitis (AS), axial spondyloarthritis (axSpA), sponsored by Akeso, Inc.. Started May 2021; status: completed.
02
Drugs
gumokimab
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on CTR20210833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210833.